Inito Secures $29 Million Series B Funding to Scale AI-Engineered At-Home Health Diagnostics Globally
What is the news?
At-home diagnostics pioneer Inito, co-founded by Indian origin founders Aayush Rai and Varun AV, has successfully closed a $29 million Series B funding news round. The investment was spearheaded by Bertelsmann India Investments, with continued support from Fireside Ventures. This significant funding milestone, which brings the company’s total capital raised to $45 million, underscores rising global confidence in India’s deep health-tech sector and the ingenuity of its founders community. The company’s unique approach leverages Artificial Intelligence to engineer synthetic antibodies, moving away from slow, inconsistent, animal-based methods, allowing for greater accuracy and stability in its diagnostic tests.
Why is it interesting?
Operating with teams in Bengaluru, Dubai, and London, Inito is transitioning its highly successful fertility monitoring system into a broader health diagnostics platform. The new capital is specifically earmarked to accelerate the development of at-home tests for a wide range of biomarkers, including testosterone, thyroid, and vitamins. Inito’s success in analyzing over 30 million hormone data points from users globally, coupled with its expansion plans targeting the United States market, firmly positions it as a Global Indian Alpha company that is building critical, scalable healthcare infrastructure for the world. This move is poised to redefine consumer health monitoring by offering clinical-grade insights directly in the comfort of a patient’s home.
Read more: Inito raises $29 Mn in Series B round led by Bertelsmann India